GLP-1 receptor agonist 1; LY3502970; OWL 833;
CAS:2212020-52-3
Chemical Formula:C48H48F2N10O5
Molecular Weight:882.97
Availability: R&D; Commercialization
⬤ CAS No.2212020-52-3
⬤ Packaging type：20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | Orforglipron |
| CAS No. | 2212020-52-3 |
| Chemical Formula | C48H48F2N10O5 |
| Molecular Weight | 882.97 |
| Related Categories | Anti-sugar API |
| Storage Conditions | Store at -20°C |
| density | 1.50±0.1 g/cm3(Predicted) |
| Solubility | Dimethyl sulfoxide: 125 mg/mL (141.57 mM) |
| Form | solid |
| Acidity coefficient (pKa) | 7.33±0.20(Predicted) |
| Color | Off-white to light yellow |
Note | Orforglipron is a novel oral GLP-1 receptor agonist (GLP-1 RA) currently in clinical trials (data as of 2023). Its safety information is mainly based on publicly available clinical research data and known risks of similar drugs, mainly manifested as gastrointestinal reactions. |
| Application | The core applications of Orforglipron API focus on type 2 diabetes and obesity. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
June 15, 2023
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
